Patient-derived xenografts: a relevant preclinical model for drug development

Identifying appropriate preclinical cancer models remains a major challenge in increasing the efficiency of drug development. A potential strategy to improve patient outcomes could be selecting the ‘right’ treatment in preclinical studies performed in patient-derived xenografts (PDXs) obtained by di...

Descripción completa

Detalles Bibliográficos
Autores principales: Pompili, Luca, Porru, Manuela, Caruso, Carla, Biroccio, Annamaria, Leonetti, Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5139018/
https://www.ncbi.nlm.nih.gov/pubmed/27919280
http://dx.doi.org/10.1186/s13046-016-0462-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5139018/
https://www.ncbi.nlm.nih.gov/pubmed/27919280
http://dx.doi.org/10.1186/s13046-016-0462-4

Ejemplares similares